ENCAB767NXE

Antibody against Homo sapiens ETF1

Homo sapiens
HepG2, K562
characterized to standards
Homo sapiens
any cell type or tissue
partially characterized
Status
released
Source (vendor)
MBLI
Product ID
RN111PW
Lot ID
001
Characterized targets
ETF1 (Homo sapiens)
Host
rabbit
Clonality
polyclonal
External resources

Characterizations

ETF1 (Homo sapiens)
Method: knockdown or knockout
Attachment from submitter
compliant
Caption
Western blot following shRNA against ETF1 in HepG2 whole cell lysate using ETF1 specific antibody. Lane 1 is a ladder, lane 2 is HepG2 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against ETF1.ETF1 protein appears as the green band, GAPDH serves as a control and appears in red.
Submitted by
Xintao Wei
Lab
Brenton Graveley, UConn
Download
ETF1 (Homo sapiens)
HepG2
Method: immunoprecipitation
Attachment from submitter
compliant
Caption
IP-Western Blot analysis of HepG2 whole cell lysate using ETF1 specific antibody. Lane 1 is 1% of twenty million whole cell lysate input and lane 2 is 25% of IP enrichment using rabbit normal IgG (lanes under 'IgG'). Lane 3 is 1% of twenty million whole cell lysate input and lane 4 is 10% IP enrichment using rabbit polyclonal anti-ETF1 antibody (lanes under 'ETF1').
Submitted by
Steven Blue
Lab
Gene Yeo, UCSD
ETF1 (Homo sapiens)
K562
Method: immunoprecipitation
Attachment from submitter
compliant
Caption
IP-Western Blot analysis of K562 whole cell lysate using ETF1 specific antibody. Lane 1 is 1% of twenty million whole cell lysate input and lane 2 is 25% of IP enrichment using rabbit normal IgG (lanes under 'IgG'). Lane 3 is 1% of twenty million whole cell lysate input and lane 4 is 10% IP enrichment using rabbit polyclonal anti-ETF1 antibody (lanes under 'ETF1').
Submitted by
Steven Blue
Lab
Gene Yeo, UCSD
ETF1 (Homo sapiens)
Method: immunoprecipitation
Attachment from submitter
Caption
IP-WB analysis of K562 whole cell lysate using ETF1 specific antibody. Lane 1 is 2.5% of five million whole cell lysate Input, lane 2 is 2.5% of supernatant after immunoprecipitation and Lane 3 is 50% of IP enrichment using rabbit polyclonal Anti-ETF1 (eRF1) pAb. This antibody passes preliminary validation and will be further pursued for primary and secondary validation.
Submitted by
Balaji Sundararaman
Lab
Gene Yeo, UCSD